Clinical intent helps pharma marketers use clinical context to guide the timing, messaging and delivery of HCP campaigns. Measurement should show whether reaching that HCP was followed by a meaningful prescribing outcome, and where data allows, a first fill or refill.
That needs to be interpreted carefully. The clinical activity that qualified the HCP for targeting may also explain why they were likely to prescribe.
HCP campaign measurement should connect clinical relevance with campaign contribution, giving marketers the evidence to refine targeting, messaging and investment.
Doceree’s Clinical Intent Signals use diagnosis, prescribing, therapy-change, access and fulfilment activity to help prioritize HCPs and inform message selection.
The campaign should retain that context across channels. Intent Powered HCP Suite extends clinical-intent-led activation across connected TV (CTV), Social through LinkedIn, and Programmatic, coordinated through Daily Command.
For measurement, connect the qualifying signal with HCP-level delivery records, timing and frequency. An HCP appearing in a target list does not establish that an advertisement reached them.
Evaluate real-time HCP targeting against whether exposure occurred while the clinical context remained relevant. Keep the targeting event separate from subsequent outcomes: a prescription recorded before an advertisement cannot have resulted from it.
The measurement framework should follow:
Clinical signals → HCP prioritization → Media activation → Prescribing outcomes → Campaign contribution
Prescription volume tells only part of the story. Start by defining which outcome the campaign is measuring and what that metric represents.
NBRx measures new-to-brand prescriptions. NRx captures new prescription activity, while TRx reflects total prescription volume, including refills. Each metric answers a different business question and should align with the campaign objective.
If the goal is HCP adoption, track first-time brand writers separately using an agreed historical window. Teams should also confirm whether the data reflects prescriptions written or dispensed and account for reporting delays before interpreting performance.
A prescription is only one point in the treatment journey. Access, affordability and fulfillment can affect whether a patient starts or continues therapy.
IQVIA’s September 2026 analysis highlights payer rejection, treatment initiation and persistence as distinct points where treatment can drop off. For marketers, this means higher prescription activity does not automatically translate into higher fill or refill activity.
When prescriptions rise but fills do not, more media may not be the answer. Access or affordability barriers may need to be examined first.
Doceree’s Care Sequence extends this view across the journey from the clinical encounter through prescription, pharmacy, fill and refill.
HCP audience prioritized using current Clinical Intent Signals may already have greater treatment opportunity. That means higher prescribing after exposure cannot automatically be credited to advertising.
Where possible, compare exposed HCPs with a similar holdout or matched group based on factors such as prior prescribing and relevant clinical activity.
If stronger outcomes appear among exposed HCPs, assess them against the comparison group, observation period and other campaign activity before interpreting the difference as prescription lift.
Because HCPs may encounter the brand across multiple channels, performance should be evaluated across the broader campaign rather than assigned to a single exposure.
HCP marketing analytics should show what to change next. Low reach may point to activation or delivery gaps, while strong reach with limited downstream movement can signal a need to review audience, timing, messaging, channel mix or the measurement window. Where a credible comparison shows stronger prescribing outcomes, the findings can inform further testing and media investment.
Pharma marketing ROI should not be reduced to prescription volume. It depends on campaign contribution, the value of the measured outcome and the cost of generating it. For smaller pharma teams, the model can stay focused: one clear objective, one primary outcome and one media decision.
Daily Command’s Analytics Workbench brings campaign exposure, Clinical Intent Signals, HCP identity, access, claims, first-party and partner data into one environment for cross-channel analysis. Connecting clinical context, media exposure and available prescribing and refill outcomes gives teams a stronger basis for deciding what to test, change or invest in next.